Possible mechanisms mediating the protective effect of cilostazol in L-arginine induced acute pancreatitis in rats: role of cGMP, cAMP, and HO-1
Autor: | Rehab Ahmed Rifaai, Asmaa Mohamed Abdel-Aziz, Seham A. Abdel-Gaber |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
Arginine medicine.medical_treatment Pharmacology Phosphodiesterase 3 Inhibitors medicine.disease_cause 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Downregulation and upregulation Cyclic AMP medicine Animals Rats Wistar Cyclic GMP Adiponectin Chemistry Insulin General Medicine Glutathione medicine.disease Cilostazol Rats Oxidative Stress Pancreatitis 030220 oncology & carcinogenesis Heme Oxygenase (Decyclizing) 030217 neurology & neurosurgery Oxidative stress medicine.drug |
Zdroj: | Naunyn-Schmiedeberg's Archives of Pharmacology. 393:1859-1870 |
ISSN: | 1432-1912 0028-1298 |
DOI: | 10.1007/s00210-020-01897-z |
Popis: | Acute pancreatitis (AP) is an inflammatory disorder with a high mortality rate. Cilostazol is a selective phosphodiesterase-3 inhibitor drug that is commonly used as an antiplatelet, antithrombotic, and vasodilator drug. It exhibits antioxidant, anti-inflammatory, and anti-apoptotic activities, but its effect on AP has not been fully elucidated yet. The present study aimed to investigate the effects of cilostazol on L-arginine-induced AP and the possible protective mechanisms. A rat model of AP was established by a single i.p. injection of 3-g/kg L-arginine on day 13 of the experiment. The treated groups received a single daily oral dose of either 100 or 300 mg/kg/day for 14 consecutive days. Rats with AP showed histopathological changes of pancreatic tissue injury together with increased serum amylase enzyme activity and decreased serum insulin, pancreatic adiponectin, and cGMP levels. Moreover, AP rats showed increased pancreatic inflammatory biomarker (TNF-α, VCAM-1, and MPO) levels with decreased anti-inflammatory IL-10 levels. In addition, oxidative stress biomarkers (MDA and NO) were increased in AP with decreased antioxidant SOD activity and GSH level. Moreover, HO-1 immunostaining was increased in the AP group. Cilostazol pretreatment reversed the histopathological change; decreased the amylase activity and the levels of TNF-α, VCAM-1, and MPO; and increased the levels of insulin, adiponectin, cGMP, cAMP, and IL-10. Moreover, cilostazol decreased MDA and NO but increased SOD and GSH. Lastly, cilostazol increased the HO-1 immunostaining more than in the AP group. These data suggest that cilostazol protects against L-arginine-induced AP, which may be related to an increase in cGMP, cAMP, and upregulation of HO-1 with subsequent anti-inflammatory and antioxidant properties. |
Databáze: | OpenAIRE |
Externí odkaz: |